HALOZYME THERAPEUTICS, INC. (HALO) earnings date
Feb 16, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 6 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Mon, May 11, 2026 | after close | 41 | 8-K |
| Q4 FY2025 | Tue, Feb 17, 2026 | after close | 48 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | after close | 34 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | after close | 36 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Tue, Feb 18, 2025 | after close | 49 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE Total Revenue Increased 39% YOY to $493 million Royalty Revenue Increased 44% YOY to $341 million Raising 2026 Financial Guidance Ranges: Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38% Royalty Revenue of $1.235 - $1.255 billion, YOY Growth of 42% - 45% Adjusted EBITDA of $1.240 - $1.290 billion, YOY Growth of 89% - 96% 1 Non-GAAP Diluted EPS of $8.75 - $9.05, YOY Growth of 111% - 118% 1 Expanded ENHANZE ® Collaboration Agreements with Three Current Partners Three E" exhibit |
| Q3 FY2026 | "“Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026,” said Darren Snellgrove, Executive Vice President and Chief Financial Officer." exhibit |
| Q3 FY2026 | "In September 2026, Halozyme and Incyte expanded their collaboration to evaluate the SC formulation of axatilimab, a monoclonal antibody targeting colony-simulating factor-1 receptor, with ENHANZE ® ." exhibit |
| Q3 FY2026 | "Financial Outlook for 2026 The Company is raising its 2026 financial guidance ranges, which were last updated on August 6, 2026." exhibit |
| Q3 FY2026 | "For the full year 2026, the Company expects:" exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37% Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43% Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95% 1 Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108% - 117% 1 Signed Five New ENHANZE ® and Hypercon ™ Collaboration " exhibit |
| Q2 FY2026 | "Based on these record results, we are raising our full year 2026 financial guidance.”" exhibit |
| Q2 FY2026 | "Financial Outlook for 2026 The Company is raising its 2026 financial guidance ranges, which were last provided on May 11, 2026." exhibit |
| Q2 FY2026 | "For the full year 2026, the Company expects:" exhibit |
| Q2 FY2026 | "Table 1. 2026 Financial Guidance Previous Guidance Range New Guidance Range Total Revenue $1.710 to $1.810 billion $1.835 to $1.910 billion Royalty Revenue $1.130 to $1.170 billion $1.220 to $1.245 billion Adjusted EBITDA 1 $1.125 to $1.205 billion $1.225 to $1.280 billion Non-GAAP Diluted EPS 1 $7.75 to $8.25 $8.65 to $9.00 1 EBITDA, Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/HALO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/HALO
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/HALO/"><img src="https://veritasdata.dev/embed/HALO.svg" alt="HALO earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/HALO/)
Script
<script async src="https://veritasdata.dev/embed/HALO.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/HALO"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.